Philip Ashton-Rickardt
Chief Tech/Sci/R&D Officer chez SIGILON THERAPEUTICS, INC.
Fortune : - $ au 31/07/2023
Profil
Philip Ashton-Rickardt was the founder of Smith Therapeutics, Inc. (founded in 2017), where he held the titles of President, CEO, Secretary & Director until 2019.
He is currently the Chief Scientific Officer at Sigilon Therapeutics, Inc. (since 2021).
Previously, he worked as the Chairman of Immunology at Imperial College London, Senior Vice President of Immunology at AZTherapies, Inc. (2019-2021), and Associate Professor at The University of Chicago (1995-2006).
Dr. Ashton-Rickardt obtained his doctorate degree from The University of Edinburgh and his undergraduate degree from King's College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 11/08/2023 | 0 ( -.--% ) | - $ | 31/07/2023 |
Postes actifs de Philip Ashton-Rickardt
| Sociétés | Poste | Début |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 14/06/2021 |
Anciens postes connus de Philip Ashton-Rickardt
| Sociétés | Poste | Fin |
|---|---|---|
AZTherapies, Inc.
 AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/06/2021 |
Smith Therapeutics, Inc.
 Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Smith Therapeutics, Inc. operates as a biopharmaceutical firm which treats neurodegenerative disease. The company was founded by Philip Ashton-Rickardt in 2017 and is headquartered in Chestnut, MA. | Founder | 31/10/2019 |
| The University of Chicago | Corporate Officer/Principal | 01/06/2006 |
| Imperial College London | Corporate Officer/Principal | - |
Formation de Philip Ashton-Rickardt
| The University of Edinburgh | Doctorate Degree |
| King's College London | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SIGILON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Health Technology |
Smith Therapeutics, Inc.
Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Smith Therapeutics, Inc. operates as a biopharmaceutical firm which treats neurodegenerative disease. The company was founded by Philip Ashton-Rickardt in 2017 and is headquartered in Chestnut, MA. | Health Technology |
